PCSAHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 1 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Processa Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Processa Pharmaceuticals, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on PCSA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $1.00 |
| 30 June 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | $6.00 |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Apr 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 6 Mar 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 17 Nov 2023 | Maxim Group | Downgrade | Hold | — |
| 4 Apr 2023 | Benchmark | Maintains | Speculative Buy | $9.00 → $4.00 |
| 3 Apr 2023 | Oppenheimer | Maintains | Outperform | $5.00 → $3.00 |
| 12 Jan 2023 | Maxim Group | Maintains | Buy | $9.00 → $5.00 |
| 19 Apr 2022 | Maxim Group | Initiates | Buy | $9.00 |
| 3 Aug 2021 | Oppenheimer | Initiates | Outperform | — |
| 2 Aug 2021 | Oppenheimer | Initiates | Outperform | — |
| 28 Oct 2020 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 42% of US stocks
Cheaper than 63% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PCSA appears on the weeks it earns a place.
Processa Pharmaceuticals, Inc. held an M&A call, and the prepared remarks transcript was published by Seeking Alpha.
Why it matters — A PCSA watcher would care because the M&A call likely outlines strategic moves such as potential acquisitions or mergers that could affect the company's direction.
Processa Pharmaceuticals acquired privately held Vidya Therapeutics in an all-stock deal, gaining access to its lead candidate being developed to target diseases involving the immune system.
Why it matters — The acquisition gives Processa a new pipeline asset aimed at immune-system diseases, potentially broadening the company's therapeutic focus beyond its current programs.
Processa Pharmaceuticals has acquired Vidya Therapeutics, gaining VT-7208, a next-generation BTK inhibitor for immune-mediated diseases. The acquisition includes a concurrent oversubscribed private placement financing of approximately $200 million.
Why it matters — The acquisition adds a potentially best-in-class BTK inhibitor to Processa's pipeline and provides funding through key clinical milestones into the second half of 2029.
Of the 1 analysts covering Processa Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Processa Pharmaceuticals, Inc. 16 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Processa Pharmaceuticals, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
No analyst covering Processa Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCSA are extrapolating price history, which says nothing about the business.
Processa Pharmaceuticals, Inc. returned -59.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies.
The most recent item we track (Seeking Alpha, 29 July 2026): "Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript". Processa Pharmaceuticals, Inc. held an M&A call, and the prepared remarks transcript was published by Seeking Alpha.
Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies. It modifies existing FDA-approved chemotherapy drugs to enhance safety and efficacy by altering their metabolism and distribution while preserving the mechanisms that target cancer cells. The company's pipeline features NGC-Cap, a next-generation capecitabine advancing in Phase 2 trials for metastatic breast cancer and gastrointestinal cancers, providing greater exposure to the active 5-FU metabolite. Additional candidates include PCS6422 for various solid tumors, PCS3117 which has completed Phase 2a trials for pancreatic, biliary tract, lung, and ovarian cancers, and PCS499 for rare kidney disease like focal segmental glomerulosclerosis through an adaptive pivotal design. Processa also pursues partnering for non-core assets such as PCS12852. These programs address unmet needs in oncology and rare diseases, aiming to improve patient outcomes in treatment-resistant cancers and debilitating conditions. Founded in 2011 and headquartered in Vero Beach, Florida, Processa Pharmaceuticals Inc. concentrates on high-potential clinical programs within the pharmaceuticals sector.
CEO Mr. George K. Ng Esq., J.D. · 12 employees · United States · https://www.processapharmaceuticals.com